Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
- None.
- None.
LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it will release its fourth quarter and full year 2023 results and operational highlights on Thursday March 14, 2024.
Management will host a conference call and webcast at 8:30 am EDT/12:30 pm GMT to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive dial-in numbers and a personal PIN, which are required to access the conference call.
A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.
Contact:
Olivia Manser
+44 (0) 7780 471 568
o.manser@autolus.com
Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com
Susan A. Noonan
S.A. Noonan Communications
+1-917-513-5303
susan@sanoonan.com
FAQ
When will Autolus Therapeutics plc release its Q4 and full year 2023 results?
What type of therapies does Autolus Therapeutics plc develop?
How can one access the conference call hosted by Autolus Therapeutics plc?
Who can be contacted for more information about Autolus Therapeutics plc?
What is the ticker symbol for Autolus Therapeutics plc?
